Highland Capital Management LLC Cuts Stock Position in GSK plc (NYSE:GSK)

Highland Capital Management LLC reduced its position in GSK plc (NYSE:GSK) by 4.0% during the fourth quarter, Holdings Channel reports. The institutional investor owned 19,672 shares of the pharmaceutical company’s stock after selling 828 shares during the quarter. Highland Capital Management LLC’s holdings in GSK were worth $665,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the company. FMR LLC boosted its holdings in GSK by 8.3% in the third quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC boosted its stake in GSK by 4.9% in the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after purchasing an additional 870,449 shares in the last quarter. Hotchkis & Wiley Capital Management LLC grew its position in GSK by 30.8% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 3,542,143 shares of the pharmaceutical company’s stock worth $144,803,000 after purchasing an additional 833,080 shares during the last quarter. Bridgewater Associates LP increased its stake in GSK by 107.3% during the 3rd quarter. Bridgewater Associates LP now owns 965,836 shares of the pharmaceutical company’s stock valued at $39,483,000 after purchasing an additional 500,010 shares in the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of GSK by 420.1% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 564,934 shares of the pharmaceutical company’s stock worth $23,095,000 after buying an additional 456,319 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors.

GSK Stock Performance

Shares of GSK stock opened at $35.20 on Friday. The stock has a market cap of $72.96 billion, a PE ratio of 22.86, a price-to-earnings-growth ratio of 1.37 and a beta of 0.63. GSK plc has a 52-week low of $31.72 and a 52-week high of $45.92. The business has a 50-day simple moving average of $34.04 and a 200-day simple moving average of $37.71. The company has a quick ratio of 0.53, a current ratio of 0.81 and a debt-to-equity ratio of 0.98.

Wall Street Analyst Weigh In

Several research firms recently issued reports on GSK. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, January 21st. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut GSK from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Six equities research analysts have rated the stock with a hold rating, one has issued a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.